Contact this trialFirst, we need to learn more about you.
Tyrosine Kinase Inhibitor
Telaglenastat + Osimertinib for Non-Small Cell Lung Cancer
Recruiting1 awardPhase 1 & 2
Pittsburgh, Pennsylvania
This trial is testing the side effects and best dose of a new drug, telaglenastat hydrochloride, when given with osimertinib to treat patients with stage IV non-small cell lung cancer that has a mutation in the EGFR gene.
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.